Abbott Laboratories - Asset Resilience Ratio
Abbott Laboratories (ABT) has an Asset Resilience Ratio of 9.19% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ABT strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1993–2024)
This chart shows how Abbott Laboratories's Asset Resilience Ratio has changed over time. See how leveraged is Abbott Laboratories's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Abbott Laboratories's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Abbott Laboratories stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $7.51 Billion | 8.92% |
| Short-term Investments | $222.00 Million | 0.26% |
| Total Liquid Assets | $7.73 Billion | 9.19% |
Asset Resilience Insights
- Limited Liquidity: Abbott Laboratories maintains only 9.19% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Abbott Laboratories Industry Peers by Asset Resilience Ratio
Compare Abbott Laboratories's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
Annual Asset Resilience Ratio for Abbott Laboratories (1993–2024)
The table below shows the annual Asset Resilience Ratio data for Abbott Laboratories.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.79% | $7.97 Billion | $81.41 Billion | -0.16pp |
| 2023-12-31 | 9.94% | $7.28 Billion | $73.21 Billion | -3.72pp |
| 2022-12-31 | 13.66% | $10.17 Billion | $74.44 Billion | +0.03pp |
| 2021-12-31 | 13.63% | $10.25 Billion | $75.20 Billion | +3.78pp |
| 2020-12-31 | 9.85% | $7.15 Billion | $72.55 Billion | +3.75pp |
| 2019-12-31 | 6.10% | $4.14 Billion | $67.89 Billion | +0.02pp |
| 2018-12-31 | 6.08% | $4.09 Billion | $67.17 Billion | -6.52pp |
| 2017-12-31 | 12.60% | $9.61 Billion | $76.25 Billion | -21.53pp |
| 2016-12-31 | 34.13% | $18.77 Billion | $55.01 Billion | +31.58pp |
| 2015-12-31 | 2.55% | $1.12 Billion | $44.00 Billion | +1.65pp |
| 2014-12-31 | 0.91% | $397.00 Million | $43.79 Billion | -9.86pp |
| 2013-12-31 | 10.76% | $4.62 Billion | $42.95 Billion | +4.26pp |
| 2012-12-31 | 6.50% | $4.37 Billion | $67.23 Billion | +4.37pp |
| 2011-12-31 | 2.13% | $1.28 Billion | $60.28 Billion | -0.85pp |
| 2010-12-31 | 2.98% | $1.80 Billion | $60.57 Billion | +0.84pp |
| 2009-12-31 | 2.14% | $1.12 Billion | $52.58 Billion | -0.15pp |
| 2008-12-31 | 2.28% | $967.60 Million | $42.42 Billion | +1.36pp |
| 2007-12-31 | 0.92% | $364.44 Million | $39.71 Billion | -1.44pp |
| 2006-12-31 | 2.36% | $852.24 Million | $36.18 Billion | +2.14pp |
| 2005-12-31 | 0.21% | $62.41 Million | $29.14 Billion | -2.68pp |
| 2004-12-31 | 2.90% | $833.33 Million | $28.77 Billion | +1.81pp |
| 2003-12-31 | 1.09% | $291.30 Million | $26.72 Billion | +0.01pp |
| 2002-12-31 | 1.08% | $261.68 Million | $24.26 Billion | +0.84pp |
| 2001-12-31 | 0.24% | $56.16 Million | $23.30 Billion | -1.35pp |
| 2000-12-31 | 1.59% | $242.50 Million | $15.28 Billion | +0.79pp |
| 1999-12-31 | 0.80% | $115.20 Million | $14.47 Billion | +0.23pp |
| 1998-12-31 | 0.57% | $75.09 Million | $13.22 Billion | +0.33pp |
| 1997-12-31 | 0.24% | $28.99 Million | $12.06 Billion | +0.12pp |
| 1996-12-31 | 0.12% | $12.88 Million | $11.13 Billion | -0.25pp |
| 1995-12-31 | 0.37% | $34.50 Million | $9.41 Billion | +0.07pp |
| 1994-12-31 | 0.29% | $25.06 Million | $8.52 Billion | -0.72pp |
| 1993-12-31 | 1.02% | $78.15 Million | $7.69 Billion | -- |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary s… Read more